Literature DB >> 9951693

Combined radiation and chemotherapy in posttransplant lymphoproliferative disorder.

D E Tsai1, E A Stadtmauer, D J Canaday, D J Vaughn.   

Abstract

The optimal treatment for posttransplant lymphoproliferative disorder which has progressed despite a reduction in immunosuppression has not been defined. We report on two patients with stage I posttransplant lymphoproliferative disorder who developed progressive disease despite a reduction in the level of immunosuppression. Both patients were treated with combined short course CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed by involved-field radiation therapy. In both patients, a rapid response was obtained followed by complete remission. Combined modality therapy can be utilized successfully in progressive limited stage posttransplant lymphoproliferative disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9951693     DOI: 10.1007/BF02787213

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

1.  Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation.

Authors:  J D Pirsch; R J Stratta; H W Sollinger; G R Hafez; A M D'Alessandro; M Kalayoglu; F O Belzer
Journal:  Am J Med       Date:  1989-02       Impact factor: 4.965

2.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

3.  Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

Authors:  A Fischer; S Blanche; J Le Bidois; P Bordigoni; J L Garnier; P Niaudet; F Morinet; F Le Deist; A M Fischer; C Griscelli
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

4.  Clinical characteristics of post-transplant lymphoproliferative disorders.

Authors:  V A Morrison; D L Dunn; J C Manivel; K J Gajl-Peczalska; B A Peterson
Journal:  Am J Med       Date:  1994-07       Impact factor: 4.965

5.  Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center.

Authors:  V Leblond; L Sutton; R Dorent; F Davi; M O Bitker; J Gabarre; F Charlotte; J J Ghoussoub; C Fourcade; A Fischer
Journal:  J Clin Oncol       Date:  1995-04       Impact factor: 44.544

6.  Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.

Authors:  E M McKelvey; J A Gottlieb; H E Wilson; A Haut; R W Talley; R Stephens; M Lane; J F Gamble; S E Jones; P N Grozea; J Gutterman; C Coltman; T E Moon
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

7.  Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease.

Authors:  A Savoie; C Perpête; L Carpentier; J Joncas; C Alfieri
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

8.  Anti-B cell antibodies for the treatment of monoclonal Epstein-Barr virus-induced lymphoproliferative syndrome after multivisceral transplantation.

Authors:  A I Lazarovits; L A Tibbles; D R Grant; C N Ghent; W J Wall; M J White; J H Joncas
Journal:  Clin Invest Med       Date:  1994-12       Impact factor: 0.825

9.  A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder.

Authors:  E J Alfrey; A L Friedman; R A Grossman; L J Perloff; A Naji; C F Barker; K T Montone; J E Tomaszewski; C Chmielewski; T Holland
Journal:  Transplantation       Date:  1992-08       Impact factor: 4.939

10.  Aggressive treatment for postcardiac transplant lymphoproliferation.

Authors:  L J Swinnen; G M Mullen; T J Carr; M R Costanzo; R I Fisher
Journal:  Blood       Date:  1995-11-01       Impact factor: 22.113

View more
  2 in total

1.  Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★).

Authors:  R Reshef; S Vardhanabhuti; M R Luskin; D F Heitjan; D Hadjiliadis; S Goral; K L Krok; L R Goldberg; D L Porter; E A Stadtmauer; D E Tsai
Journal:  Am J Transplant       Date:  2011-01-10       Impact factor: 8.086

Review 2.  Post-transplant lymphoproliferative disorder in the pelvis successfully treated with consolidative radiotherapy.

Authors:  Omar Habibeh; Khaled Elsayad; Jan Kriz; Uwe Haverkamp; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2016-06-22       Impact factor: 3.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.